Mertiva AB

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Pioneering Diamyd® Study to Prevent Childhood Diabetes Approved

Wed, Mar 04, 2009 09:48 CET

Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd® diabetes vaccine in children with high risk to develop type 1 diabetes.At Malmö University Hospital, Lund University in Sweden, large screening tests results in a continuous identification of children that are subject to a very high risk of developing type 1 diabetes. By measuring different biomarkers in blood samples, it is possible to determine in an early stage that these children are in the autoimmune disease process that destroys their insulin producing cells. If vaccination

Diamyd receives new approval for study to follow Swedish children and confirm long-term effect of the Diamyd® diabetes vaccine

Mon, Feb 16, 2009 13:06 CET

Diamyd Medical has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company’s Phase II study of the Diamyd® diabetes vaccine, which started four years ago. The aim of the follow-up study is to confirm the vaccine’s long-term effect.“Clinical studies with Diamyd® have demonstrated significant efficacy in preserving the body’s own ability to produce insulin,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “We will now, in parallel with our ongoing large international Phase III trials, establish that the

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Pioneering Diamyd® Study to Prevent Childhood Diabetes Approved

Diamyd receives new approval for study to follow Swedish children and confirm long-term effect of the Diamyd® diabetes vaccine

Media